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Cost-effectiveness of FDA variance for blood 
collection from individuals with hereditary 
hemochromatosis at a 398-bed hospital-
based donor center
D.M. Gribble, D.J. Chaffin, and B.J. Bryant
Hereditary hemochromatosis (HH) is treated by therapeutic phlebot-
omy to reduce excess body iron. This 398-bed, hospital-based donor 
center wanted to determine whether there was a financial advantage 
to requesting FDA approval to allow transfusion of blood components 
from eligible individuals with HH. Donor center records from 2008 
were reviewed to identify all therapeutic phlebotomy patients with a di-
agnosis of HH. HH patients were contacted and asked to complete the 
AABB Uniform Donor History Questionnaire (UDHQ) to determine 
their eligibility as potential allogeneic blood donors. Financial ramifica-
tions attributable to loss of revenue from the therapeutic phlebotomies 
($100/collection) were compared with the potential gain in revenue 
from collecting units for transfusion ($429/collection) in a 12-month 
period. Nineteen HH patients were identified and screened for allo-
geneic eligibility. Seventeen patients (89%) met the eligibility criteria 
for allogeneic donors, and two patients (11%) did not. Retrospective 
review of donor records indicated that a total of 60 units were collected 
from these HH patients from January 2008 through December 2008. 
Fifty-five of the 60 units collected (92%) were eligible for allogeneic 
use, potentially generating gross revenue of $23,595. After deducting 
expenses for infectious disease testing and loss of revenue for the non-
qualified therapeutic phlebotomies, the net revenue from the collection 
of 55 RBC units that could have potentially been used for allogeneic 
transfusion was $20,345. In contrast, the current revenue generated 
by the collection of 60 therapeutic phlebotomies was only $6,000. In 
2008, using eligible HH individuals as allogeneic blood donors would 
have resulted in an increase in revenue of $14,345 for our blood center. 
This study demonstrates that even at a medium-size, hospital-based 
donor center, obtaining a variance from the FDA to establish an HH 
blood donor program is a cost-effective endeavor, which does not com-
promise donor or patient safety.
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Hereditary hemochromatosis (HH) is an autosomal recessive genetic disorder of iron metabolism and is one of the most commonly inherited disorders in 
Caucasians of northern European descent. A single nucle-
otide mutation in the HFE gene resulting in a C282Y sub-
stitution is responsible for most of the classic cases of HH. 
When hemochromatosis is present, iron absorption in the 
gastrointestinal tract is increased and iron stores are gradu-
ally saturated over a prolonged period. There is progressive 
deposition of excess iron in body tissues, which leads to tox-
ic levels of iron and organ damage and can eventually lead 
to death. Iron toxicity can affect most organs, but the liver, 
pancreas, and heart are particularly affected. HH is treated 
by phlebotomy, which reduces body iron by removing the 
hemoglobin found in the RBCs. Regular phlebotomy thera-
py safely reduces the iron stores in most patients. Early ini-
tiation of therapeutic phlebotomy procedures before organ 
damage has occurred may restore normal life expectancy 
and improve symptoms.
 On the basis of the currently understood molecular 
mechanisms of the disease, there is no evidence HH can be 
transmitted by means of blood transfusion. Additionally, 
there is no evidence to suggest that blood donated from in-
dividuals with HH would carry any added risk for the trans-
fusion recipient provided the donor meets all the current 
standards for allogeneic blood donation. Blood from HH 
patients has been used for transfusion in the United States 
and other countries without reports of adverse effects in re-
cipients.1,2
 Currently, the US Food and Drug Administration (FDA) 
does not prohibit the use of blood from therapeutic collec-
tions from otherwise eligible donors, but it requires that 
blood intended for transfusion be labeled with the donor’s 
disease (21 CFR 640.3(d)). The Code of Federal Regulations 
requires that blood withdrawn to promote the health of a 
donor shall not be used as a source of whole blood, unless 
the container label conspicuously indicates the donor’s dis-
ease necessitating the withdrawal of blood. This labeling 
requirement represents an almost insurmountable obstacle 
to the use of the blood in clinical transfusion settings. In 
addition, regulations state that a person may donate a unit 
of blood more than once in 8 weeks only after a physical 
examination and certification of health by a physician (21 
CFR 640.3(f)). Labeling and regulatory requirements are 
the primary reasons that blood from HH individuals is not 
routinely collected for transfusion.
 The FDA approved a final variance for collecting alloge-
neic blood from individuals with a diagnosis of HH in Au-
gust 2001 that addresses the regulatory issues and labeling 
requirements.3 In this variance, the FDA allows a blood col-
lection facility to include an alternative procedure to 21 CFR 
640.3(d) to distribute blood and blood components collect-
ed from individuals with diagnosed HH without indicating 
the donor’s disorder on the container label as long as they 
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met all other allogeneic criteria for blood donations. This 
guidance document also addresses concerns that individu-
als with HH would have an incentive to seek blood dona-
tion as a cost-free alternative to their therapeutic (medical) 
phlebotomy and possibly deny risk-associated behaviors 
that might preclude cost-free donations.
Material and Methods   
 This study was designed to evaluate the financial im-
pact on our 398-bed hospital-based donor center of collect-
ing blood for transfusion from HH patients who met the 
eligibility requirements for allogeneic donations. Our donor 
center has provided therapeutic phlebotomy services to the 
community for more than 15 years and serves patients with 
a broad range of diagnoses in the various stages of treat-
ment. Monthly statistics from the donor center were used 
to categorize all therapeutic collections into two groups: 
(1) individuals with a diagnosis of HH, and (2) individuals 
with all other diagnoses. This was necessary to determine 
the number and percentage of HH therapeutic donations 
annually.
 Loss of revenue from providing free therapeutic 
phlebotomy collections for individuals with HH ($100/
collection) was compared with the potential gain in rev-
enue generated by collecting additional RBC units ($429/
collection) from eligible HH donors in a 12-month period. 
Collection costs related to staffing were not considered rele-
vant as it would cost the same to collect a unit that would be 
further processed or discarded. It was also determined that 
any cost increase related to supplies (collection bags) and 
additional processing time would be offset by a decrease in 
costs associated with biohazardous waste disposal. The two 
factors that would affect the potential net revenue in col-
lecting HH individuals as allogeneic donors were the addi-
tional expense of infectious disease testing and the expense 
of providing therapeutic phlebotomies free of charge to all 
HH patients regardless of their ability to meet eligibility cri-
teria for allogeneic donations as required by the FDA vari-
ance guidance.
 HH patients undergoing therapeutic phlebotomy treat-
ments were contacted by telephone and asked whether they 
would be willing to participate in the study. Those express-
ing interest in participating were asked to complete the 
AABB “Uniform Donor History Questionnaire” (UDHQ) 
V1.1 when they presented to the donor center for their next 
scheduled therapeutic phlebotomy. Written informed con-
sent for study participation was documented on the UDHQ. 
The completed UDHQ was used to screen the HH individu-
als to determine their eligibility as allogeneic donors as part 
of this study. They were categorized into two groups: (1) 
individuals who qualified as allogeneic donors by meeting 
all FDA and other standard eligibility criteria, and (2) indi-
viduals who did not qualify as allogeneic donors by current 
eligibility criteria. The donor eligibility determined from the 
UDHQ and frequencies of donation were recorded into an 
Excel (Microsoft Corp., Redmond, WA) spreadsheet from 
January 2008 through December 2008.
Results
 Records of all patients presenting to our facility for 
therapeutic phlebotomies in 2008 were reviewed, and 41 
percent (60 of 146) were from patients diagnosed with HH 
(Table 1). Nineteen individuals were eligible for the study 
based on documentation of their diagnosis of HH from 
written requests to perform therapeutic phlebotomies by 
physician prescriptions. All gave informed consent to par-
ticipate in the study.
 The nineteen HH patients were screened for allogeneic 
eligibility using the AABB UDHQ V1.1. Seventeen patients 
(89%) met the eligibility criteria for allogeneic donors as 
defined by the UDHQ, and two patients (11%) did not. For 
the purpose of this study, it was assumed that the 17 do-
nors meeting eligibility requirements for allogeneic dona-
tion would have met the requirements for the preceding 
12-month study timeframe. Retrospective review of donor 
records indicated that a total of 60 units were collected 
from HH patients from January 2008 through December 
2008. The average collection was 5 units per month. As il-
lustrated by the donation frequencies of the HH donors in 
Table 2, donors were in the various stages of therapeutic 
phlebotomy treatments (induction versus maintenance) 
during this study. Fifty-five of the 60 units collected (92%) 
were eligible for allogeneic use as defined by the UDHQ 
and could be potentially introduced into the blood supply 
(Table 2). The remaining 5 units (8%) were not eligible for 
allogeneic use as defined by UDHQ donor criteria and were 
discarded. Introduction of 55 RBC units into the blood bank 
inventory would have potentially generated gross revenue 
of $23,595. 
Table 1. Therapeutic phlebotomy collections in 2008
Diagnoses Jan Feb Mar Apr May June July Aug Sept Oct Nov Dec Total
HH 5 6 8 4 4 5 3 4 6 5 4 6 60
Non-HH 10 9 13 9 3 4 4 4 8 8 10 4 86
Total 15 15 21 13 7 9 7 8 14 13 14 10 146
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Discussion
 The collection and disposal costs associ-
ated with the 5 units that could not be used 
for allogeneic transfusion would have totaled 
$500. Infectious disease testing would have 
been required on the remaining 55 units at 
$50 per unit, for a total expense of $2,750. 
Net revenue from the collection of an addi-
tional 55 RBC units that could have poten-
tially been used for allogeneic transfusion was 
$20,345. By comparison, the current revenue 
generated by the collection of 60 therapeutic 
phlebotomies was $6,000 (Fig. 1).
Conclusion   
 This study was conducted at a 398-bed 
community hospital–based donor center 
located in a predominantly Caucasian com-
munity (55% Caucasian, 35% Hispanic, 2% 
African American) of approximately 100,000 
residents. Although the number of HH indi-
viduals and the total number of units they 
donated as part of this study was relatively 
small, the potential to generate additional 
revenue from the currently discarded collec-
tions was substantial. In 2008, using eligible 
Fig. 1  Potential and current net revenues from hereditary hemochromatosis 
donors in 2008. 
Table 2. Donor eligibility and donation frequency for hereditary hemochromatosis donors in 2008
Donor 
No. UDHQ Eligibility Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Total
1 Y 1 1 1 1 1 1 0 1 1 0 0 1 9
2 Y 1 0 0 0 1 0 0 0 1 0 0 0 3
3 Y 0 1 1 0 0 1 1 1 1 1 0 0 7
4 N 0 1 0 1 0 0 0 0 0 0 0 1 3
5 Y 1 1 0 0 1 0 0 1 0 1 1 0 6
6 Y 0 1 0 0 0 0 0 0 0 0 0 0 1
7 Y 0 1 0 0 0 0 0 0 0 0 0 0 1
8 Y 0 0 1 0 0 0 0 0 0 0 0 1 2
9 Y 0 0 1 0 0 0 1 0 0 1 0 0 3
10 Y 0 0 1 0 1 0 0 0 0 0 0 0 2
11 Y 0 0 1 0 0 0 0 0 0 0 0 0 1
12 Y 0 0 0 1 0 0 0 0 0 0 0 0 1
13 Y 0 0 0 0 0 1 0 0 0 0 0 0 1
14 Y 0 0 1 0 0 1 0 0 1 0 0 1 4
15 Y 1 0 1 1 0 1 1 0 1 0 0 1 7
16 Y 0 0 0 0 0 0 0 1 0 0 0 0 1
17 N 1 0 0 0 0 0 0 0 1 0 0 0 2
18 Y 0 0 0 0 0 0 0 0 0 2 3 1 6
19 Y 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 5 6 8 4 4 5 3 4 6 5 4 6 60
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HH individuals as allogeneic blood donors would have re-
sulted in an increase in revenue of more than $14,345 for 
our blood center. The data from this study demonstrate that 
even at a medium-sized, hospital-based donor center, ob-
taining a variance from the FDA to collect and use blood 
from HH donors is a cost-effective endeavor, which does 
not compromise donor or patient safety.
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